Molecular characterization of rheumatoid arthritis with magnetic resonance imaging

Topics in Magnetic Resonance Imaging

Volumn 22, Issue 2, 2011, Pages 61-69

  Gu, Jeffrey T ^a   Nguyen, Linda ^a   Chaudhari, Abhijit J ^b   MacKenzie, John D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FERRIC OXIDE; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; MAGNETITE; MYELOPEROXIDASE; PYRUVIC ACID; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

CARBON NUCLEAR MAGNETIC RESONANCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DNA DAMAGE; ENZYME ACTIVITY; EPIGENETICS; FEASIBILITY STUDY; GLUCOSE METABOLISM; HUMAN; HYDRODYNAMICS; HYPERPOLARIZATION; IN VITRO STUDY; IONIZING RADIATION; LEUKOCYTE; LOW TEMPERATURE; MACROPHAGE; MAGNETIC FIELD; MICROWAVE IRRADIATION; MOLECULAR IMAGING; MOLECULAR PROBE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE STRESS; PARTICLE SIZE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOFREQUENCY; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL NOISE RATIO; WHOLE BODY PET;

ARTHRITIS, RHEUMATOID; CARBON ISOTOPES; CONTRAST MEDIA; DEXTRANS; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 84862177190     PISSN: 08993459     EISSN: 15361004     Source Type: Journal    
DOI: 10.1097/RMR.0b013e31825c062c     Document Type: Review

References (84)

1. MacKenzie JD, Karasick D. Imaging of rheumatoid arthritis. In: Weissman B, ed. Imaging of Arthritis and Metabolic Bone Disease. Philadelphia, PA: Elsevier Health Sciences; 2009:340-364.
2. Sommer OJ, Kladosek A, Weiler V, et al. Rheumatoid arthritis: a practical guide to state-of-the-art imaging, image interpretation, and clinical implications. Radiographics. 2005;25:381-398. (Pubitemid 40547055)
3. McQueen FM, Ostergaard M. Established rheumatoid arthritisVnew imaging modalities. Best Pract Res Clin Rheumatol. 2007;21:841-856. (Pubitemid 47381242)
4. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med. 2006;355:704-712.
5. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727-735.
6. Emery P. Evidence supporting the benefit of early intervention in rheumatoid arthritis. J Rheumatol Suppl. 2002;66:3-8. (Pubitemid 35266004)
7. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002;46:328-346.
8. Conaghan PG, Bird P, McQueen F, et al. The OMERACT MRI inflammatory arthritis group: advances and future research priorities. J Rheumatol. 2009;36:1803-1805.
9. McQueen FM, Dalbeth N. Predicting joint damage in rheumatoid arthritis using MRI scanning. Arthritis Res Ther. 2009;11:124.
10. Gompels LL, Paleolog EM. A window on disease pathogenesis and potential therapeutic strategies: molecular imaging for arthritis. Arthritis Res Ther. 2011;13:201.
11. Taylor P, Gartemann J, Hsieh J, et al. A systematic review of serum biomarkers antiYcyclic citrullinated peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmune Dis. 2011;2011:815038.
12. MacKenzie JD, Yen YF, Mayer D, et al. Detection of inflammatory arthritis by using hyperpolarized 13C-pyruvate with MR imaging and spectroscopy. Radiology. 2011;259:414-420.
13. Larson PE, Gold GE. Science to practice: can inflammatory arthritis be monitored by using MR imaging with injected hyperpolarized 13C-pyruvate? Radiology. 2011;259:309-310.
14. Mansson S, Johansson E, Magnusson P, et al. 13C imagingVa new diagnostic platform. Eur Radiol. 2006;16:57-67. (Pubitemid 43103569)
15. Kohler SJ, Yen Y, Wolber J, et al. In vivo 13 carbon metabolic imaging at 3T with hyperpolarized 13C-1-pyruvate. Magn Reson Med. 2007;58:65-69. (Pubitemid 47229918)
16. Ardenkjaer-Larsen JH, Fridlund B, Gram A, et al. Increase in signal-to-noise ratio of 910,000 times in liquid-state NMR. Proc Natl Acad Sci U S A. 2003;100:10158-10163. (Pubitemid 37071849)
17. Golman K, Ardenkjaer-Larsen JH, Petersson JS, et al. Molecular imaging with endogenous substances. Proc Natl Acad Sci U S A. 2003;100:10435-10439. (Pubitemid 37071896)
18. Damyanovich AZ, Staples JR, Chan AD, et al. Comparative study of normal and osteoarthritic canine synovial fluid using 500 MHz 1H magnetic resonance spectroscopy. J Orthop Res. 1999;17:223-231. (Pubitemid 29190495)
19. Falchuk KH, Goetzl EJ, Kulka JP. Respiratory gases of synovial fluids. An approach to synovial tissue circulatory-metabolic imbalance in rheumatoid arthritis. Am J Med. 1970;49:223-231.
20. Fink MP. Ethyl pyruvate: a novel anti-inflammatory agent. J Intern Med. 2007;261:349-362. (Pubitemid 46474763)
21. Hitchon CA, El-Gabalawy HS, Bezabeh T. Characterization of synovial tissue from arthritis patients: a proton magnetic resonance spectroscopic investigation. Rheumatol Int. 2009;29:1205-1211.
22. Meshitsuka S, Yamazaki E, Inoue M, et al. Nuclear magnetic resonance studies of synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Clin Chim Acta. 1999;281:163-167. (Pubitemid 29142325)
23. Naughton D, Whelan M, Smith EC, et al. An investigation of the abnormal metabolic status of synovial fluid from patients with rheumatoid arthritis by high field proton nuclear magnetic resonance spectroscopy. FEBS Lett. 1993;317:135-138. (Pubitemid 23043956)
24. Naughton DP, Haywood R, Blake DR, et al. A comparative evaluation of the metabolic profiles of normal and inflammatory knee-joint synovial fluids by high resolution proton NMR spectroscopy. FEBS Lett. 1993;332:221-225. (Pubitemid 23305327)
25. Gallagher FA, Bohndiek SE, Kettunen MI, et al. Hyperpolarized 13CMRI and PET: in vivo tumor biochemistry. J NuclMed. 2011;52:1333-1336.
26. Wilson DM, Keshari KR, Larson PE, et al. Multi-compound polarization by DNP allows simultaneous assessment of multiple enzymatic activities in vivo. J Magn Reson. 2010;205:141-147.
27. Corot C, Petry KG, Trivedi R, et al. Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging. Invest Radiol. 2004;39:619-625. (Pubitemid 39287601)
28. Beckmann N, Falk R, Zurbrügg S, et al. Macrophage infiltration into the rat knee detected by MRI in a model of antigen-induced arthritis. Magn Reson Med. 2003;49:1047-1055. (Pubitemid 36627284)
29. Dardzinski BJ, Schmithorst VJ, Holland SK, et al. MR imaging of murine arthritis using ultrasmall superparamagnetic iron oxide particles. Magn Reson Imaging. 2001;19:1209-1216. (Pubitemid 34016586)
30. Lutz AM, Seemayer C, Corot C, et al. Detection of synovial macrophages in an experimental rabbit model of antigen-induced arthritis: ultrasmall superparamagnetic iron oxideYenhanced MR imaging. Radiology. 2004;233:149-157. (Pubitemid 39280969)
31. Perez JM, Simeone FJ, Tsourkas A, et al. Peroxidase substrate nanosensors for MR imaging. Nano Lett. 2004;4:119-122. (Pubitemid 38167875)
32. Reynolds PR, Larkman DJ, Haskard DO, et al. Detection of vascular expression of E-selectin in vivo with MR imaging. Radiology. 2006;241:469-476. (Pubitemid 44632893)
33. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol. 2001;11:2319-2331. (Pubitemid 33041104)
34. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005;26:3995-4021. (Pubitemid 40044762)
35. Kooi ME, Heeneman S, Daemen MJAP, et al. The emerging role of USPIOs forMRimaging of atherosclerosis. In: Bulte JWM, Modo MMJ, eds. Nanoparticles in Biomedical Imaging. New York, NY: Springer; 2008:63-90.
36. Peng XH, Qian X, Mao H, et al. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine. 2008;3:311-321.
37. Lodhia J, Mandarano G, Ferris N, et al. Development and use of iron oxide nanoparticles (part 1): synthesis of iron oxide nanoparticles for MRI. Biomed Imaging Interv J. 2010;6:e12.
38. Thorek DL, Chen AK, Czupryna J, et al. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng. 2006;34:23-38.
39. Elias A, Tsourkas A. Imaging circulating cells and lymphoid tissues with iron oxide nanoparticles. Hematology Am Soc Hematol Educ Program. 2009;2009:720-726.
40. Kelly KA, Allport JR, Tsourkas A, et al. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res. 2005;96:327-336. (Pubitemid 40279907)
41. Artemov D, Mori N, Okollie B, et al. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med. 2003;49:403-408. (Pubitemid 36262806)
42. Morishige K, Kacher DF, Libby P, et al. High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis. Circulation. 2010;122:1707-1715.
43. Kamat M, El-Boubbou K, Zhu DC, et al. Hyaluronic acid immobilized magnetic nanoparticles for active targeting and imaging of macrophages. Bioconjug Chem. 2010;21:2128-2135.
44. Wellicome SM, Kapahi P, Mason JC, et al. Detection of a circulating form of vascular cell adhesion molecule-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol. 1993;92:412-418. (Pubitemid 23183748)
45. Mundinger A, Ioannidou M, Meske S, et al. MRI of knee arthritis in rheumatoid arthritis and spondylarthropathies. Rheumatol Int. 1991;11:183-186.
46. Di Marco M, Sadun C, Port M, et al. Physicochemical characterization of ultrasmall superparamagnetic iron oxide particles (USPIO) for biomedical application as MRI contrast agents. Int J Nanomedicine. 2007;2:609-622.
47. Kansas GS. Selectins and their ligands: current concepts and controversies. Blood. 1996;88:3259-3287. (Pubitemid 26365560)
48. Singh N, Jenkins GJS, Asadi R, et al. Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). 2010;5358:1-15.
49. Dumarey N, Egrise D, Blocklet D, et al. Imaging Infection with 18F-FDGYlabeled leukocyte PET/CT: initial experience in 21 patients. J Nucl Med. 2006;47:625-632 (Pubitemid 46768463)
50. Roivainen A, Parkkola R, Yli-Kerttula T, et al. Use of positron emission tomography with methyl-11C-choline and 2-18F-fluoro-2-deoxy-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium. Arthritis Rheum. 2003;48:3077-3084 (Pubitemid 37409318)
51. Cherry SR, Louie AY, Jacobs RE. The integration of positron emission tomography with magnetic resonance imaging. Proc IEEE. 2008;96:416-438.
52. Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med. 2000;41:661.
53. Kim JH, Lee JS, Kang KW, et al. Whole-body distribution and radiation dosimetry of (68)Ga-NOTA-RGD, a positron emission tomography agent for angiogenesis imaging. Cancer Biother Radiopharm. 2012;27:65-71.
54. Gaertner FC, Souvatzoglou M, Brix G, et al. Imaging of hypoxia using PET and MRI. Curr Pharm Biotechnol. 2012;13:552-570.
55. Karstila K, Korpela M, Sihvonen S, et al. Prognosis of clinical renal disease and incidence of new renal findings in patients with rheumatoid arthritis: follow-up of a population-based study. Clin Rheumatol. 2007;26:2089-2095. (Pubitemid 350120347)
56. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol. 2007;2: 264-267.
57. Kubota K, Ito K, Morooka M, et al. FDG PET for rheumatoid arthritis: basic considerations and whole-body PET/CT. Ann N Y Acad Sci. 2011;1228:29-38.
58. Kubota K, Ito K, Morooka M, et al. Whole-body FDG-PET/CT on rheumatoid arthritis of large joints. Ann Nucl Med. 2009;23:783-791.
59. Fox JJ, Autran-Blanc E, Morris MJ, et al. Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT. J Nucl Med. 2011;52:1727-1732.
60. Schenck J. The role of magnetic susceptibility in magnetic resonance imaging: MRI magnetic compatibility of the first and second kinds. Med Phys. 1996;23:815.
61. Bernstein M, Huston 3rd J, Ward H. Imaging artifacts at 3.0 T. J Magn Reson Imaging. 2006;24:735.
62. Boesen M, Østergaard M, Cimmino MA, et al. MRI quantification of rheumatoid arthritis: current knowledge and future perspectives. Eur J Radiol. 2009;71:189-196.
63. Kubassova O, Boesen M, Cimmino MA, et al. A computer-aided detection system for rheumatoid arthritis MRI data interpretation and quantification of synovial activity. Eur J Radiol. 2010;74:e67Ye72.
64. Palmer WE, Rosenthal DI, Schoenberg OI, et al. Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1995;196:647-655
65. Beckers C, Ribbens C, Andre B, et al. Assessment of disease activity in rheumatoid arthritis with 18F-FDG PET. J Nucl Med. 2004;45:956-964. (Pubitemid 47611682)
66. Nakamura H, Masuko K, Yudoh K, et al. Positron emission tomography with 18F-FDG in osteoarthritic knee. Osteoarthritis Cartilage. 2007;15:673-681. (Pubitemid 46760620)
67. Hustinx R, Malaise MG. PET imaging of arthritis. PET Clin. 2006;1:131-139.
68. Goerres GW, Forster A, Uebelhart D, et al. F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis. Clin Nucl Med. 2006;31:386-390. (Pubitemid 44315517)
69. Fleming A, Crown J, Corbett M. Early rheumatoid disease. I. Onset. Ann Rheum Dis. 1976;35:357.
70. Bowen SL, Wu Y, Chaudhari AJ, et al. Initial characterization of a dedicated breast PET/CT scanner during human imaging. J Nucl Med. 2009;50:1401-1408.
71. Chaudhari AJ, Bowen SL, Burkett GW, et al. High-resolution 18F-FDG PET with MRI for monitoring response to treatment in rheumatoid arthritis. Eur J Nucl Med Mol Imaging. 2010;37:1047.
72. Chaudhari AJ, Ferrero A, Godinez F, et al. Molecular imaging of rheumatoid, psoriatic and osteoarthritis in the hand [abstract]. Arthritis Rheum. 2011;63:206.
73. Chaudhari AJ, Burkett GW, Bowen SL, et al. Multimodality high resolution wrist imaging for monitoring response to therapy in rheumatoid arthritis: instrumentation and techniques. In: IEEE Nuclear Science Symposium Conference Record. Piscataway, NJ: IEEE 2008:4840-4844.
74. Catana C, Procissi D, Wu Y, et al. Simultaneous in vivo positron emission tomography and magnetic resonance imaging. Proc Natl Acad Sci U S A. 2008;105:3705.
75. Judenhofer MS, Wehrl HF, Newport DF, et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med. 2008;14:459-465. (Pubitemid 351499385)
76. Miese F, Scherer A, Ostendorf B, et al. Hybrid 18F-FDG PET-MRI of the hand in rheumatoid arthritis: initial results. Clin Rheumatol. 2011;30:1247-1250.
77. Herzog H, Pietrzyk U, Shah NJ, et al. The current state, challenges and perspectives of MR-PET. Neuroimage. 2010;49:2072-2082.
78. Catana C, van der Kouwe A, Benner T, et al. Toward implementing an MRI-based PET attenuation-correction method for neurologic studies on the MR-PET brain prototype. J Nucl Med. 2010;51: 1431-1438.
79. Horton SC, Emery P. Biological therapy for rheumatoid arthritis: where are we now? Br J Hosp Med (Lond). 2012;73:12-18.
80. Ma MH, Ibrahim F, Walker D, et al. Remission in early rheumatoid arthritis: predicting treatment response. J Rheumatol. 2012;39:470-475.
81. Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med. 2001;111:446-451. (Pubitemid 33016415)
82. Elzinga EH, van der Laken CJ, Comans EFI, et al. 18F-FDG PET as a tool to predict the clinical outcome of infliximab treatment of rheumatoid arthritis: an explorative study. J Nucl Med. 2011;52:77.
83. Ostergaard M, Peterfy C, Conaghan P, et al. OMERACT rheumatoid arthritis magnetic resonance imaging studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol. 2003;30:1385-1386. (Pubitemid 36666373)
84. Tan AL, Tanner S, Waller M, et al. Regional differences in bone metabolism in the DIP joint in psoriatic arthritis compared to osteoarthritis support the concept of an integrated bone-enthesis nail apparatusVa high-resolution 18F-fluoride positron emission tomography study [abstract]. Arthritis Rheum. 2011;63:1702.